Introduction There is currently no general agreement on how to best conceptualize dissociative symptoms and whether they share similar neural underpinnings across dissociative disorders. Neuroimaging data could help elucidate these questions. Objectives The objective of this review is to summarize empirical evidence for neural aberrations observed in patients suffering from dissociative symptoms. Methods A systematic literature review was conducted including patient cohorts diagnosed with primary dissociative disorders, post-traumatic stress disorder (PTSD), or borderline personality disorder. Results Results from MRI studies reporting structural (gray matter and white matter) and functional (during resting-state and task-related activation) brain aberrations were extracted and integrated. In total, 33 articles were included of which 10 pertained to voxel-based morphology, 2 to diffusion tensor imaging, 10 to resting-state fMRI, and 11 to task-related fMRI. Overall findings indicated aberrations spread across diverse brain regions, especially in the temporal and frontal cortices. Patients with dissociative identity disorder and with dissociative PTSD showed more overlap in brain activation than each group showed with depersonalization/derealization disorder. Conclusion In conjunction, the results indicate that dissociative processing cannot be localized to a few distinctive brain regions but rather corresponds to differential neural signatures depending on the symptom constellation.Background In patients with stable coronary heart disease, it is not known whether achievement of standard of care (SOC) targets in addition to evidence-based medicine (EBM) is associated with lower major adverse cardiovascular events (MACE) cardiovascular death, myocardial infarction, and stroke. Methods EBM use was recommended in the STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY trial. SOC targets were blood pressure (BP) less then 140/90 mm Hg and low-density lipoprotein-cholesterol (LDL-C) less then 100 mg/dL and less then 70 mg/dL. In patients with diabetes, glycosylated hemoglobin A1c (HbA1c) less then 7% and BP of less then 130/80 mm Hg were recommended. Feedback to investigators about rates of EBM and SOC was provided regularly. Results In 13,623 patients, 1-year landmark analysis assessed the association between EBM, SOC targets, and MACE during follow-up of 2.7 years (median) after adjustment in a Cox proportional hazards model. At 1 year, aspirin was prescribed in 92.5% of patients, statins in 97.2%, β-blockers in 79.0%, and angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers in 76.9%. MACE was lower with LDL-C less then 100 mg/dL (70-99 mg/dL) compared with LDL-C ≥ 100 mg/dL (hazard ratio [HR] 0.694, 95% CI 0.594-0.811) and lower with LDL-C less then 70 mg/dL compared with LDL-C less then 100 mg/dL (70-99 mg/dL) (HR 0.834, 95% CI 0.708-0.983). MACE was lower with HbA1c less then 7% compared with HbA1c ≥ 7% (HR 0.705, 95% CI 0.573-0.866). There was no effect of BP targets on MACE. Conclusions MACE was lower with LDL-C less then 100 mg/dL (70-99 mg/dL) and even lower with LDL-C less then 70 mg/dL. MACE in patients with diabetes was lower with HbA1c less then 7%. Achievement of targets is associated with improved patient outcomes.Introduction Biallelic damaging variants in ALPK3, encoding alpha-protein kinase 3, cause pediatric-onset cardiomyopathy with manifestations that are incompletely defined. Methods and results We analyzed clinical manifestations of damaging biallelic ALPK3 variants in 19 pediatric patients, including nine previously published cases. Among these, 11 loss-of-function (LoF) variants, seven compound LoF and deleterious missense variants, and one homozygous deleterious missense variant were identified. Among 18 live-born patients, 8 exhibited neonatal dilated cardiomyopathy (44.4%; 95% CI 21.5%-69.2%) that subsequently transitioned into ventricular hypertrophy. The majority of patients had extracardiac phenotypes, including contractures, scoliosis, cleft palate, and facial dysmorphisms. We observed no association between variant type or location, disease severity, and/or extracardiac manifestations. Myocardial histopathology showed focal cardiomyocyte hypertrophy, subendocardial fibroelastosis in patients under 4 yiomyopathy. Adults with ALPK3 LoF variants therefore warrant evaluations for cardiomyopathy.Lanthanum-modified bentonite (LMB) is a widely used phosphorus-inactivating agent in lakes. However, dissolved organic carbon (DOC) exists ubiquitously in lakes, and its influence on phosphate binding is still not adequately understood. Our results showed that both phosphate and DOC can be adsorbed by LMB. The Langmuir adsorption maxima of phosphate and DOC were 9.06 mg P/g and 5.31 mg C/g, respectively, generating a C/P molar ratio ∼1.5. When phosphate and DOC coexisted at this ratio, the adsorption of phosphate was not influenced by DOC and vice versa. However, the phosphate capture by LMB was significantly reduced by raising the ratio above ∼9, and the reduction was increased with increasing the ratio. Once adsorbed by LMB, phosphate was essentially not desorbed by DOC, while adsorbed DOC can be mostly liberated by phosphate. It is deemed that phosphate can interact preferentially with La on LMB. However, DOC can still be adsorbed by LMB, even after LMB was saturated with phosphate, which was attributed to (i) the high coordination capacity of La; (ii) the interaction of DOC with the hydroxyl group(s) of the adsorbed phosphate via hydrogen bonding; and (iii) the interaction of DOC with the La sites unoccupied by phosphate. We proposed that LMB can be applied in the season (time) when the DOC/P ratio in lakes is low enough to facilitate the adsorption of phosphate, which will no longer be released into water, even after the C/P ratio is raised later.Sertraline is one of the most commonly prescribed antidepressants in the last few years. Therefore, it is not surprising that it is regularly detected in wastewaters, surface waters, sediments, biosolids and biota. Effluents from wastewater treatment plants are the main contributors to its presence in the environment. The presented study aims to elucidate the processes involved in its removal, concentrating mainly on sorption and biodegradation during wastewater treatment. We performed our laboratory scale experiments in two sets of experiments 1) batch biodegradation and sorption experiments and 2) flow-through laboratory scale pilot wastewater treatment bioreactors. The batch experiments revealed that sorption to activated sludge was the leading removal process, eliminating up to 90% of sertraline present in the batches.  https://www.selleckchem.com/products/carfilzomib-pr-171.html  Biodegradation was however the secondary removal process, influenced by the presence of alternative easily biodegradable carbon sources. We postulated chemical structures of ten detected biotransformation products.